1. Development Background and Technical Needs in Alternative Toxicology
1.1 Limitations of Traditional Toxicology Methods
Traditional toxicology relies on animal testing and two-dimensional cell cultures, which have significant drawbacks: animal testing fails to accurately predict about 60% of hepatotoxic drugs due to interspecies differences (e.g., mouse vs. human liver metabolism), as seen in the troglitazone incident. It is also challenging to simulate complex disease phenotypes and capture chronic toxicity, while facing ethical controversies. Two-dimensional cell cultures lack three-dimensional structure, leading to abnormal activity of metabolic enzymes (e.g., CYP3A4). In terms of cost efficiency, preclinical toxicity testing for new drugs requires $150 million and 6 years, with 90% of candidates failing due to toxicity, making low-throughput and high-cost animal testing a barrier to research and development.
1.2 The Rise and Development of Alternative Toxicology
In April 2025, the FDA announced a gradual phase-out of traditional animal testing in favor of organoids and organ-on-a-chip testing for drug safety. The European Union plans to release a roadmap for the elimination of animal testing in chemical safety assessments in the same year, while the UK has banned vertebrate pesticide testing when alternatives are available. Global policies are driving alternative toxicology to become mainstream, reshaping drug development and safety assessment paradigms.
1.3 Advantages of Organ-on-a-Chip and Organoid Technologies
The core advantage of both technologies lies in “organoids providing cellular complexity + chips providing dynamic environments.” The resulting organ-on-a-chip (OrgOC) can cover the entire drug development process. By integrating AI to analyze biological data, it can shorten development cycles by 40%-70% and reduce costs by 35%-60%, enhancing efficiency and reliability in early discovery, compound optimization, preclinical research, and clinical trial phases.
2. Technical Principles and Development History of Organ-on-a-Chip and Organoids
2.1 Technical Principles and Structure of Organ-on-a-Chip
Organ-on-a-chip technology is centered around microfluidic systems, etching channels on polymer materials such as PDMS, and arranging organ-specific cell layers. It maintains functionality through a blood-like fluid, with advantages including: dynamic simulation of microenvironments (fluid, mechanical signals), multi-organ integration (e.g., MIT’s “Human on a Chip” achieving interconnection of 10 organs with an error margin of ±5%), high fidelity controllability, and real-time monitoring of metabolic and toxicity indicators.
2.2 Technical Principles and Construction Methods of Organoids
Organoids are formed through the self-organization of stem cells, retaining the heterogeneity and functionality of the original tissue. Their construction relies on: self-organization of stem cells (e.g., liver organoids simulating metabolic enzymes, intestinal organoids reproducing barrier functions), three-dimensional matrix (e.g., Matrigel) culture, organ-specific signal regulation, and spontaneous formation of structural polarity (e.g., intestinal crypts – villi).
2.3 Technological Integration and Collaborative Innovation: Organoid Chips
Since the introduction of the lung chip in 2012, the integration of multi-organ chips and organoid technology has led to the creation of “organoid chips.” A 2022 study published in Nature Biotechnology showed that liver organoid chips had a 40% higher accuracy in predicting hepatotoxicity compared to traditional methods, allowing for the study of inter-organ interactions (e.g., gut-liver axis, blood-brain barrier). A typical case is the use of Southeast University’s cardiac organoid chip for in vitro toxicity assessment.
2.4 Development History and Key Milestones
1. Early Exploration (2009-2012): Successful culture of human intestinal organoids in 2009, first lung chip introduced in 2012;
2. Technological Expansion (2013-2018): Development of liver, kidney, intestinal chips and multi-organ organoids for disease modeling;
3. Integrated Innovation (2019-2022): Rise of organoid chips, with the FDA prioritizing IND applications for organ chips in 2021;
4. Acceleration of Commercialization (2023-2025): FDA to release a roadmap for reducing preclinical animal testing by 2025;
5. Comprehensive Application (2025 to Present): Technology becomes widespread, with the FDA launching the DILI prediction validation project in collaboration with 3RsC in July 2025.
3. Application Scenarios of Organ-on-a-Chip and Organoids in Alternative Toxicology
3.1 Applications in Drug Development
• Early Discovery: Accelerates disease modeling and target screening, with organoids retaining organ-specific functions (e.g., CYP450 enzymes);
• Preclinical Evaluation: Emulate liver chip has an 87% accuracy in identifying DILI compounds (100% for non-DILI), recognized by the FDA for pilot studies;
• Metabolic Research: Gut-liver co-culture chips dynamically monitor first-pass metabolism; a pharmaceutical company used liver-heart tandem chips to discover a metabolite causing QT prolongation, preventing a $200 million loss;
• Personalized Medicine: Patient-derived tumor organoids (PDO) predict chemotherapy efficacy, with cases where antibiotic-induced liver toxicity was avoided through chip testing.
3.2 Applications in Cosmetic Safety Assessment
Following the EU’s ban on animal testing under the Cosmetics Directive, the technology has been widely applied: Epithelix skin chips simulate barrier functions, complying with OECD 439 standards for irritation testing; eye organoid chips replace the Draize rabbit eye test; an international company used the SkinEthic RHE model to shorten testing cycles and reduce costs.
3.3 Applications in Environmental Toxicology
• Air Pollutants: Epithelix three-dimensional airway models assess PM2.5 and ozone toxicity;
• Water Environmental Pollutants: Kirkstall tandem chips simulate the lung-liver axis, revealing carbon nanotube-induced liver fibrosis;
• Nanomaterials: Southeast University’s cardiac organoid chip tracks microplastic toxicity, discovering mechanisms of oxidative stress and fibrosis;
• Case Study: Liver organoids simulate PFAS dose-dependent toxicity (EC50>650μM), revealing synergistic liver injury mechanisms of microplastics and bisphenol A.
3.4 Other Application Scenarios
• Personalized Medicine: Patient organoids predict treatment toxicity, such as guiding clinical decisions for tumor drug sensitivity;
• Rare Disease Research: Cystic fibrosis patient organoids assist in mechanism studies and targeted drug development;
• Regenerative Medicine: Chips study stem cell differentiation, while organoids explore alternative sources for organ transplantation;
• Case Study: Patient liver organoids simulate hereditary liver disease, screening potential therapeutic drugs.
4. Commercial Progress of Organ-on-a-Chip and Organoids
4.1 Market Size and Growth Trends
• Global: The organoid and organ-on-a-chip market is expected to reach $5 billion by 2025 (annual growth > 30%), with the organ-on-a-chip market at $1.87 billion (62% for drug development). By 2033, the organ-on-a-chip market will reach $2.34 billion (annual growth 32.03%);
• China: The market is projected to reach $700 million by 2025 (with $1.2 billion by 2030, annual growth of 11.4%), and the personalized medicine sector is expected to exceed $1.2 billion by 2030 (annual growth > 30%). By 2025, the industry scale will exceed 5 billion yuan, with domestic equipment accounting for 45%;
• Driving Factors: Policy support (FDA, EPA), technological advancements, long-term cost savings of 70%, and expansion of application scenarios.
4.2 Major Companies and Product Analysis
• Global Tier:
1. First Tier: Emulate (USA, liver chip with 87% DILI accuracy), CN Bio (UK, PhysioMimix platform);
2. Second Tier: Hesperos (USA, multi-organ coupling models, high-end service market of $320 million), Epithelix (Switzerland, airway models certified by ISO/OECD);
3. Third Tier: Kirkstall (UK, tandem chips simulating ADME processes);
• Chinese Characteristics: Beijing DaXiang Technology (Series B funding of $300 million for GMP production line), WuXi AppTec (Asia’s largest OOC center, testing 100,000 chips annually);
• Product Types: Standardized consumables ($2000-5000, with 120,000 units shipped by 2025), integrated systems ($250,000, reducing R&D costs by 40%), and customized services (mainly for multinational pharmaceutical companies).
4.3 Technological Innovations and R&D Progress
• Materials: Nanofiber scaffolds extend liver chip metabolic function to 28 days, with 3D bioprinting/degradable hydrogel chips growing at 31%/28% annually;
• Detection: Neural chips integrate microelectrode arrays, increasing throughput by 10 times; YaoSu Technology’s MPS platform combines AI image recognition, participating in FDA DILI projects;
• Multi-Organ Integration: MIT’s “Human on a Chip” connects 10 organs, with liver-kidney combinations and tumor microenvironment chips becoming hotspots;
• AI Integration: Axiom Bio AI predicts toxicity, with Hutton’s OPERA tool achieving 87% accuracy (updated version 91%);
• Organoid Breakthroughs: CRISPR editing constructs disease models, such as CYP2C9*2 mutations warning of drug-induced cholestasis.
4.4 Policy Support and Regulatory Dynamics
• USA: In 2025, the FDA will release a NAMs replacement framework, initiating a pilot for non-animal testing monoclonal antibodies, and in July, collaborating with 3RsC on DILI validation;
• EU: OECD will incorporate chip data into GLP by 2024, with REACH requiring 30% of chemicals to use non-animal models by 2026;
• China: WuXi AppTec – China National Institute of Food and Drug Control’s “Organ-on-a-Chip GLP System” will be validated in 2024, with lung cancer organoid efficacy prediction accuracy at 83.3%;
• International Cooperation: 3RsC tests liver models from 9 companies, with EPA and OECD promoting standardization.
5. Future Prospects of Organ-on-a-Chip and Organoid Technologies
5.1 Trends in Technological Development
• Deepening Integration: Organoid chips integrate biological complexity and controllability;
• Multi-Organ Integration: “Human on a Chip” simulates system-level physiological processes;
• AI + Automation: Full-process automation and AI toxicity prediction;
• High-Throughput Miniaturization: Single chips integrating multiple modules, reducing costs and promoting widespread use;
• Personalized Applications: iPSC-derived organoids support precision medicine.
5.2 Market Development Forecast
• Scale: The global organ-on-a-chip market will reach $2.34 billion by 2033, with China’s personalized medicine sector reaching $1.2 billion by 2030;
• Region: North America leads (43% share), with China growing at 35%, and Europe excelling in clinical applications of organoids;
• Applications: Drug development remains dominant (62%), with regenerative medicine reaching $800 million by 2030.
5.3 Challenges and Response Strategies
• Challenges: Technical (standardization, throughput, complexity), commercialization (cost, acceptance, oligopoly competition);
• Responses:
1. Establish unified standards (e.g., FDA DILI validation project);
2. Promote industry-academia-research collaboration (e.g., the US “Human Chip Program”);
3. Lower technical barriers (automation systems + standardized reagent kits);
4. Promote regulatory recognition (participate in policy formulation);
5. Expand application scenarios (personalized medicine, regenerative medicine).
6. Conclusion
Organ-on-a-chip and organoid technologies simulate human organ functions, addressing interspecies differences in traditional animal testing while offering ethical and cost advantages. They have been widely applied in drug development, cosmetic/environmental toxicology, and personalized medicine. The global market is expected to reach $5 billion by 2025, with policies and technology accelerating commercialization. In the future, through multidisciplinary integration, system-level simulation will be achieved, transitioning toxicology from “experience-driven” to “data precision,” ultimately realizing the vision of “zero animal testing” and providing scientific assurance for health and environmental protection.